#97 Alpha Score 92.6

CryptoCondom

@crypto_condom · tracked since Jan 2026
97
BUZZBERG The leaderboard is ranked by Alpha Score, which weighs a speaker's average return, their number of calls, and reputation — a credibility rating of the source that can only raise a score, never lower it. Read the FAQ
Alpha Score 92.6
Calls
79
Win Rate
49.4%
return
+7.3%
Calls 79 3918 Posts tracked · 16.0/day Posted today
Calls
7d 2
30d 4
90d 13
Best Calls
HYPE Long +161.7%
ABSI Long +146.6%
ABCL Long +131.5%
Worst Calls
UBS Short -49.0%
GRAL Short -48.1%
LAC Long -45.8%
Most Mentioned
BB ×39
LPTH ×39
IOVA ×33
Recent Calls
SFTBY Short 1 day ago
ARB Long 2 days ago
CVS Short 2 weeks ago
Win Rate 49% Long 45 Short 34
Win Rate
7d 57%
30d 61%
90d 52%
Average Return +7.3% Long Return +17.6% Short Return -7.2%
Average Return
7d +2.2%
30d +3.1%
90d +2.8%
Loading charts...
Result
Result
Sort
Theme Stance
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Apr 30
$5.34
+43.3%
Bought BlackBerry calls; BB pivoted from phones to autonomous software, has memetic potential, growing revenue and defense contracts for future FCF.
Bought BlackBerry calls; BB pivoted from phones to autonomous software, has memetic potential, growing revenue and defense contracts for future FCF.
Cybersecurity
Long
Apr 06
$10.91
-11.7%
Opened new spot LightPath long at $11; $480m mkt cap on $42m confirmed revenue, EBITDA-positive, sees the company as cheap.
Opened new spot LightPath long at $11; $480m mkt cap on $42m confirmed revenue, EBITDA-positive, sees the company as cheap.
AI Photonics
Long
May 29
$4.31
+100.0%
Buy IOVA for its unique FDA-approved TIL therapy, upcoming ASCO data, strong patent protection, and high probability of acquisition given scalability limitations and long cash runway.
Buy IOVA for its unique FDA-approved TIL therapy, upcoming ASCO data, strong patent protection, and high probability of acquisition given scalability limitations and long cash runway.
Pharma & Biotech
Long
Jan 23
$3.99
-18.8%
DNN: single-name uranium bull with fundamentals
Buy DNN as a high-conviction single-name uranium play; author reviewed financials and filings and found fundamentals compelling, adding it to an existing multi-year uranium bull thesis previously expressed through URA.
Critical Minerals
Long
May 04
$4.63
+131.5%
Took ABCL position as counter to ABSI; ABCL generates antibodies vs known epitopes and is breaking out technically.
Took ABCL position as counter to ABSI; ABCL generates antibodies vs known epitopes and is breaking out technically.
Pharma & Biotech
Long
Jan 12
$5.53
-45.8%
USG stake + commodities rally fuel LAC upside
Buy LAC as a government-owned 10% stake creates political favoritism risk/reward; with commodities rallying on geopolitics, a declining dollar, and threatened central bank independence, speaker expects a sharp near-term move higher driven by USG-backed nepotism catalyst.
Critical Minerals
Long
Jan 02
$46.01
-3.4%
URA held as 2026 commodities allocation
Author discloses URA (uranium ETF) as a current 2026 portfolio holding in the commodities bucket; no per-ticker reasoning given beyond sector allocation.
Thematic ETFs
Long
Mar 16
$11.04
+5.1%
Long AGRO via a lot of Sept 2026 calls; AGRO is a Tether proxy (74% owned), with earnings catalyst after its M&A of Profertil, LatAM's largest urea producer.
Long AGRO via a lot of Sept 2026 calls; AGRO is a Tether proxy (74% owned), with earnings catalyst after its M&A of Profertil, LatAM's largest urea producer.
Packaged Foods
Short
Jan 28
$77.80
+4.5%
Short CVNA, fraud thesis gaining traction
Short CVNA on fraud allegations gaining mainstream traction; speaker maintains an active short position citing the stock as fraudulent, with the thesis now entering broader market awareness as a potential catalyst for accelerated downside.
Retail & Mobility
Long
Apr 17
$3.58
+146.6%
Bull case for Absci: AI proliferating oncology/therapeutics; highlights ABSI funded through 2028 as de-risking the long.
Bull case for Absci: AI proliferating oncology/therapeutics; highlights ABSI funded through 2028 as de-risking the long.
Pharma & Biotech
Short
Feb 13
$300.52
+4.8%
JPM puts: expense miss, insider selling, credit risk
Short JPM via puts targeting $200s — MACD momentum deteriorating, projected expenses of $105B exceed analyst estimates of $102-103B, C-suite insiders (CFO + General Counsel) sold 5-10% of holdings in early 2026, with additional headwinds from sunbelt real estate credit risk, Trump's 10% card rate cap, and debanking reputational damage.
Banks
Long
Feb 02
$31.00
+161.7%
Buy HYPE: decentralized, global, anonymous prediction markets.
Buy HYPE; the tweet touts HYPE prediction markets as decentralized, native, global and anonymous, and cheers the opportunity with "giddyup."
Crypto Assets
Long
Mar 18
$199.62
+6.1%
Buying equities that benefit from second-order effects of the war, naming CVX; moving the book to more cash plus these names.
Buying equities that benefit from second-order effects of the war, naming CVX; moving the book to more cash plus these names.
Oil & Gas
Long
Jan 31
$1.67
-38.9%
Author holding ZRO, adding at $1.50
Author discloses an active ZRO (LayerZero) position and expresses intent to add more at the $1.50 level, signaling conviction in the current holding.
Crypto Assets
Long
Jan 11
$14.57
+26.6%
Author backs XPRO as 2026 energy bet
Author names XPRO as a personal energy sector bet for 2026; no specific catalyst given beyond sector conviction and forward positioning intent.
Oil & Gas
Showing 15 of 79 calls · sorted by mentions

CryptoCondom has 79 trade ideas tracked on Buzzberg across 72 tickers since January 2026. Win rate 49% across 77 evaluated calls, average return +7.3%. Ranked #97 on the Buzzberg Alpha leaderboard. Most covered: BB, LPTH, IOVA.